(Press-News.org) There's been a breakthrough in the case of the missing planets.
While planet-hunting missions have discovered thousands of worlds orbiting distant stars, there's a severe scarcity of exoplanets that measure between 1.5 and two times Earth's radius. That's the middle ground between rocky super-Earths and larger, gas-shrouded planets called mini-Neptunes. Since discovering this 'radius gap' in 2017, scientists have been sleuthing out why there are so few midsize heavenly bodies.
The new clue arose from a fresh way of looking at the data. A team of researchers led by the Flatiron Institute's Trevor David investigated whether the radius gap changes as planets age. They divvied up exoplanets into two groups -- young and old -- and reassessed the gap. The least common planet radii from the younger set were smaller on average than the least common ones from the older set, they found. While the scarcest size for younger planets was about 1.6 times Earth's radius, it's about 1.8 times Earth's radius at older ages.
The implication, the researchers propose, is that some mini-Neptunes shrink drastically over billions of years as their atmospheres leak away, leaving behind only a solid core. By losing their gas, the mini-Neptunes "jump" the planet radius gap and become super-Earths. As time goes on, the radius gap shifts as larger and larger mini-Neptunes make the jump, transforming into larger and larger super-Earths. The gap, in other words, is the chasm between the largest-size super-Earths and the smallest-size mini-Neptunes that can still retain their atmospheres. The researchers END
Shrinking planets could explain mystery of universe's missing worlds
Studying data from the Kepler space telescope, Flatiron Institute researchers found that planetary shrinkage over billions of years likely explains a yearslong mystery: The scarcity of planets roughly double Earth's size
2021-05-17
ELSE PRESS RELEASES FROM THIS DATE:
Apixaban not superior to standard care after TAVR
2021-05-17
The blood thinner apixaban was not superior to standard of care following transcatheter aortic valve replacement (TAVR), according to findings from a new trial called ATLANTIS presented at the American College of Cardiology's 70th Annual Scientific Session. Researchers found that while apixaban reduced the formation of blood clots (thrombosis) around the implanted valve with no increased bleeding risk, a subset of patients taking apixaban who did not have an indication for anticoagulation apart from the TAVR procedure showed a tendency toward a higher rate of non-cardiovascular death--a ...
Left atrial appendage occlusion associated with low rate of stroke
2021-05-17
Transcatheter left atrial appendage occlusion (LAAO) with a WATCHMAN device was associated with a low rate of stroke at one year even among older patients with atrial fibrillation (AFib) who faced a high risk for stroke or bleeding based on their previous health history, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.
The WATCHMAN device, which blocks a small portion of the heart to help reduce the risk of a dangerous clot forming, was approved by the U.S. Food and Drug Administration in 2015. The device is used to reduce the risk of stroke in patients with AFib, a heart rhythm disorder, that is not caused by problems with the heart valve. ...
Left atrial appendage occlusion reduces stroke after heart surgery
2021-05-17
Patients with an elevated risk of stroke due to heart rhythm problems, or atrial fibrillation (AFib), were much less likely to suffer a stroke after undergoing heart surgery if doctors concurrently performed an additional procedure, called left atrial appendage occlusion (LAAO), according to the results of a trial presented at the American College of Cardiology's 70th Annual Scientific Session.
AFib increases a person's risk of stroke or systemic embolism, which are life-threatening conditions caused by blood clots blocking an artery. It has been hypothesized that the blood clots that cause these conditions often originate in the left atrial appendage, a small sac on the upper left chamber of the heart. LAAO is a procedure to ...
Sacubitril/valsartan does not outperform ACE inhibitor after heart attack
2021-05-17
The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks. Findings from the PARADISE-MI trial were presented at the American College of Cardiology's 70th Annual Scientific Session.
The study is the first large trial to examine whether sacubitril/valsartan can reduce heart failure and associated hospitalizations and deaths in patients post-heart attack who face a high risk of developing heart failure. Patients taking sacubitril/valsartan were about 10% less likely than those ...
Baby and regular-strength aspirin work equally well to protect heart health
2021-05-17
Researchers found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg), also called baby aspirin, versus 325 mg of daily aspirin, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.
Aspirin is the most common medication for people with established cardiovascular disease--for example, those who have had a heart attack, a stent placed or bypass surgery--to help prevent another heart attack, stroke or premature death. But despite aspirin's proven and widespread use, there has been no evidence as to whether low-dose aspirin (81 mg) or regular-strength (325 mg) aspirin is ...
Renal denervation lowers blood pressure in medication-resistant hypertension
2021-05-17
Two months after undergoing renal denervation (RDN), patients with high blood pressure who did not respond to treatment with multiple medications had a greater reduction in daytime systolic blood pressure than patients who did not receive RDN, with no difference in major adverse effects, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
Patients who received RDN--a procedure that delivers energy to overactive nerves in the kidneys to decrease their activity--saw a median reduction of 8 mmHg in their daytime ambulatory systolic blood ...
Burnout rates double for cardiology clinicians amid COVID-19
2021-05-17
The coronavirus pandemic has upended nearly every aspect of everyday life and continues to have devastating effects worldwide. It has also taken a significant toll on cardiovascular clinicians, many of whom provide direct care to patients with COVID-19, according to results of a new survey presented at the American College of Cardiology's 70th Annual Scientific Session.
Among those surveyed, burnout increased from 20% to 38% during the peak of the pandemic. Rates of burnout pre- and peak COVID-19 increased across all members of the cardiology team and was particularly striking among cardiovascular team members, ...
Clopidogrel superior to aspirin for long-term post-stent maintenance
2021-05-17
Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long-term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy (DAPT) following the insertion of a coronary stent. After two years of follow-up, chronic maintenance therapy with clopidogrel resulted in a 30% reduction in deaths, heart attacks, strokes or major bleeding events, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
"These data ...
No improvement in outcomes with rapid, high-sensitivity troponin T testing protocol at one year
2021-05-17
Using more sensitive and frequent repeat testing of a blood test that indicates heart injury to guide the treatment of low-risk patients with symptoms of a possible heart attack resulted in patients being discharged earlier and receiving fewer cardiac stress tests but did not improve patient outcomes after one year, according to research presented at the American College of Cardiology's 70th Annual Scientific Session. In fact, a subset of patients receiving this more sensitive and frequent blood testing protocol were more likely to have a heart attack or to die during the one-year follow-up period compared with patients whose treatment was informed by the results of conventional blood testing procedures.
Troponins are proteins found in ...
De-escalation of dual antiplatelet therapy appears safe and effective
2021-05-17
Among patients who had a cardiac stent inserted after a heart attack, switching to less-potent dual antiplatelet therapy (DAPT) after 30 days was safer and more effective in preventing adverse events a year later than continuing on a high-potency DAPT regimen, according to data presented at the American College of Cardiology's 70th Annual Scientific Session.
"We have shown that, in patients who have had a heart attack and who've been treated with newer-generation stents and guideline-recommended medical therapy, de-escalation of DAPT by switching from ticagrelor to clopidogrel is completely safe and more effective than continuing to treat patients with ticagrelor," said Kiyuk Chang, MD, professor of Cardiology, Division of Internal Medicine at the Catholic University of ...
LAST 30 PRESS RELEASES:
Making lighter work of calculating fluid and heat flow
Normalizing blood sugar can halve heart attack risk
Lowering blood sugar cuts heart attack risk in people with prediabetes
Study links genetic variants to risk of blinding eye disease in premature infants
Non-opioid ‘pain sponge’ therapy halts cartilage degeneration and relieves chronic pain
AI can pick up cultural values by mimicking how kids learn
China’s ecological redlines offer fast track to 30 x 30 global conservation goal
Invisible indoor threats: emerging household contaminants and their growing risks to human health
Adding antibody treatment to chemo boosts outcomes for children with rare cancer
Germline pathogenic variants among women without a history of breast cancer
Tanning beds triple melanoma risk, potentially causing broad DNA damage
Unique bond identified as key to viral infection speed
Indoor tanning makes youthful skin much older on a genetic level
Mouse model sheds new light on the causes and potential solutions to human GI problems linked to muscular dystrophy
The Journal of Nuclear Medicine ahead-of-print tip sheet: December 12, 2025
Smarter tools for peering into the microscopic world
Applications open for funding to conduct research in the Kinsey Institute archives
Global measure underestimates the severity of food insecurity
Child survivors of critical illness are missing out on timely follow up care
Risk-based vs annual breast cancer screening / the WISDOM randomized clinical trial
University of Toronto launches Electric Vehicle Innovation Ontario to accelerate advanced EV technologies and build Canada’s innovation advantage
Early relapse predicts poor outcomes in aggressive blood cancer
American College of Lifestyle Medicine applauds two CMS models aligned with lifestyle medicine practice and reimbursement
Clinical trial finds cannabis use not a barrier to quitting nicotine vaping
Supplemental nutrition assistance program policies and food insecurity
Switching immune cells to “night mode” could limit damage after a heart attack, study suggests
URI-based Global RIghts Project report spotlights continued troubling trends in worldwide inhumane treatment
Neutrophils are less aggressive at night, explaining why nighttime heart attacks cause less damage than daytime events
Menopausal hormone therapy may not pose breast cancer risk for women with BRCA mutations
Mobile health tool may improve quality of life for adolescent and young adult breast cancer survivors
[Press-News.org] Shrinking planets could explain mystery of universe's missing worldsStudying data from the Kepler space telescope, Flatiron Institute researchers found that planetary shrinkage over billions of years likely explains a yearslong mystery: The scarcity of planets roughly double Earth's size